9 Results for "

orally active NAMPT inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "orally active NAMPT inhibitor" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-136241
CAS No.: 1800487-55-1
Purity:  99.87%
Target:  

NAMPT Caspase

Research Areas:  

Cancer

OT-82 is a potent, selective and orally active inhibitor of NAMPT. OT-82 is selectively toxic to cells of hematopoietic origin and?induces cell death in a NAD + dependent manner. OT-82 is a promising antineoplastic agent for the study of hematological malignancies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12628
CAS No.: 1362151-42-5
Purity:  99.89%
Target:  

NAMPT

Research Areas:  

Cancer

GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC50 of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .
loading...
    loading...
Cat. No.: HY-176237
CAS No.: 3077970-44-3
Target:  

NAMPT Apoptosis

Research Areas:  

Cancer

Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC50 of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD + and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .
loading...
    loading...
Cat. No.: HY-175294
CAS No.: 3054043-85-2
Target:  

PD-1/PD-L1 NAMPT

Research Areas:  

Cancer

PD-L1/Nampt-IN-1 is an orally active inhibitor that simultaneously target PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50s value of 63 nM and 582 nM. PD-L1/Nampt-IN-1 demonstrates cross-species affinity with comparable KD values for hPD-L1 (52.6 nM) and mPD-L1 (49.1 nM), respectively. PD-L1/Nampt-IN-1 effectively inhibits tumor growth by activating the tumor immune microenvironment. PD-L1/Nampt-IN-1 can be used for the study of melanoma .
loading...
    loading...
Cat. No.: HY-148572
CAS No.: 2247884-06-4
Research Areas:  

Cancer

NAMPT/IDO1-IN-1 is an orally active dual inhibitor of NAMPT and IDO1 with IC50s of 57.7 nM and 233 nM, respectively. NAMPT/IDO1-IN-1 blocks NAD+ biosynthesis, inhibits proliferation and migration of Paclitaxel (HY-B0015)- and FK866 (HY-50876)-resistant NSCLC cell lines (A549/R cells). NAMPT/IDO1-IN-1 has shown antitumor effects in mice and enhanced A549/R cell sensitivity to paclitaxel .
loading...
    loading...
Cat. No.: HY-181578
CAS No.: 3077970-78-3
Target:  

NAMPT Apoptosis

Research Areas:  

Cancer

Nampt-IN-17 is an selective orally active NAMPT inhibitor with a human NAMPT IC50 of 17 nM and Ki of 25.9 nM. Nampt-IN-17 depletes intracellular NAD + and ATP, disrupts mitochondrial membrane potential, suppresses cell proliferation, self-renewal, invasion, and migration, induces cell-cycle arrest and apoptosis. Nampt-IN-17 exhibits selective activity against NAPRT-deficient gastric cancer cells. Nampt-IN-17 can be used for the research of NAPRT-deficient gastric cancer .
loading...
    loading...
Cat. No.: HY-181863
Research Areas:  

Cancer

Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers .
loading...
    loading...
Cat. No.: HY-182567
CAS No.: 2109805-79-8
Target:  

NAMPT

Research Areas:  

Cancer

Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human Ki of 5.6 nM. Nampt-IN-19 blocks NAD + biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-184650
Target:  

SHP2 NAMPT Apoptosis ERK

Research Areas:  

Cancer

SHP2/NAMPT-IN-1 is an orally active dual inhibitor of SHP2 and NAMPT, with IC50 values of 30.5 nM and 24.4 nM, respectively. SHP2/NAMPT-IN-1 reduces NAD+ levels and p-ERK expression by inhibiting NAMPT. SHP2/NAMPT-IN-1 can inhibit the migration and colony formation of MDA-MB-231 cells and promote apoptosis. SHP2/NAMPT-IN-1 has anti-proliferative activity against a variety of tumor cell lines and can reverse PD-L1-mediated T-cell immunosuppression. SHP2/NAMPT-IN-1 can be used for breast cancer research .
loading...
    loading...